{
    "Trade/Device Name(s)": [
        "YSI 2900C Biochemistry Analyzer"
    ],
    "Submitter Information": "YSI Incorporated",
    "510(k) Number": "K210933",
    "Predicate Device Reference 510(k) Number(s)": [
        "K913806"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA"
    ],
    "Summary Letter Date": "May 5, 2023",
    "Summary Letter Received Date": "May 15, 2023",
    "Submission Date": "September 26, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Venous whole blood",
        "Fingerstick capillary whole blood",
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Vials",
        "Tubes"
    ],
    "Instrument(s)/Platform(s)": [
        "YSI 2900C Biochemistry Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme mediated electrochemical detection",
        "Coulometry",
        "Potentiostatic amperometry"
    ],
    "Methodologies": [
        "Enzyme-coupled electrochemical detection"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Instrument",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for YSI 2900C Biochemistry Analyzer, a semi-automated laboratory instrument for in vitro quantitative glucose measurement in blood, serum, and plasma.",
    "Indications for Use Summary": "Intended for use by trained professionals in a laboratory setting to quantitatively measure glucose in venous whole blood, fingerstick capillary whole blood, serum, and plasma for diagnosis and treatment of carbohydrate metabolism disorders, including diabetes mellitus, idiopathic hypoglycemia, and pancreatic islet cell tumors; not for neonate screening or point-of-care use.",
    "fda_folder": "Clinical Chemistry"
}